SCHEMBL23979280

SCHEMBL23979280

CC(N)Cc1c2ccccc2cc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.55
HTR2C P28335 4/20 0.52
HTR2B P41595 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
SLC6A2 P23975 3/20 0.47
TAAR1 Q96RJ0 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
MAOA P21397 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
CYP2A6 P11509 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
ADRB1 P08588 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
HTR1E P28566 1/20 0.43
HTR7 P34969 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7915794 0.83 HTR2A (0.54) HTR2AHTR2CHTR2BL3MBTL1CYP2A6
SCHEMBL2396477 0.80 HTR2A (0.50) HTR2AL3MBTL1
SCHEMBL28130103 0.78 HTR2A (0.48) HTR2AHTR2CHTR2BL3MBTL1MAOA
SCHEMBL12436125 0.77 HTR2A (0.49) HTR2AHTR2CHTR2BSLC6A2TAAR1
Alcohol SCHEMBL9404147 0.76 HTR2A (0.46) HTR2AL3MBTL1
SCHEMBL7206762 0.76 HTR2A (0.50) HTR2AHTR2CHTR2BL3MBTL1TAAR1
SCHEMBL7206758 0.76 HTR2A (0.50) HTR2AHTR2CHTR2BL3MBTL1TAAR1
SCHEMBL3463475 0.76 HTR2A (0.55) HTR2AL3MBTL1SLC6A2TAAR1SLC6A4
SCHEMBL18647243 0.76 HTR2A (0.50) HTR2AL3MBTL1TAAR1
SCHEMBL9158178 0.76 HTR2A (0.50) HTR2AHTR2CHTR2BL3MBTL1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230114807-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2023-04-13 US disclosed
US-20210338851-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338851-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN FOLH1, KLK3, PSMA3 HTR2A 4044/4885HTR2C 3776/4885HTR2B 2765/4885
US-20230114807-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN FOLH1, KLK3, PSMA3 HTR2A 4044/4885HTR2C 3776/4885HTR2B 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.